FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029286823> ?p ?o ?g. }

• W2029286823 endingPage "5917" @default.
• W2029286823 startingPage "5908" @default.
• W2029286823 abstract "This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of CH5132799.Patients with metastatic solid tumors were eligible for the study. CH5132799 was administered orally once daily or twice daily in 28-day cycles.Thirty-eight patients with solid tumors received CH5132799 at 2 to 96 mg once daily or 48 to 72 mg twice daily. The MTD was 48 mg on the twice-daily schedule but was not reached on the once daily schedule. DLTs were grade 3 elevated liver function tests (LFT), grade 3 fatigue, grade 3 encephalopathy, grade 3 diarrhea, and grade 3 diarrhea with grade 3 stomatitis; all DLTs were reversible. Most drug-related adverse events were grade 1/2. Diarrhea (34%) and nausea (32%) were the most common events. Mean Cmax and AUC0-24 in steady state at MTD were 175 ng/mL and 1,550 ng·h/mL, respectively, consistent with efficacious exposure based on preclinical modeling. Reduction in SUVmax with [(18)F] fluorodeoxyglucose positron emission tomography (FDG-PET) was observed in 5 of 7 patients at MTD. A patient with PIK3CA-mutated clear cell carcinoma of the ovary achieved a partial response by GCIG CA125 criteria and further, a heavily pretreated patient with triple-negative breast cancer had marked improvement in her cutaneous skin lesions lasting six cycles.CH5132799 is well tolerated at the MTD dose of 48 mg twice daily. At this dose, the drug had a favorable PK and PD profile and preliminary evidence of clinical activity." @default.
• W2029286823 created "2016-06-24" @default.
• W2029286823 creator A5001343667 @default.
• W2029286823 creator A5002405477 @default.
• W2029286823 creator A5003564280 @default.
• W2029286823 creator A5009096434 @default.
• W2029286823 creator A5010813520 @default.
• W2029286823 creator A5016550047 @default.
• W2029286823 creator A5021317857 @default.
• W2029286823 creator A5032401979 @default.
• W2029286823 creator A5034748028 @default.
• W2029286823 creator A5041984199 @default.
• W2029286823 creator A5045955939 @default.
• W2029286823 creator A5061059772 @default.
• W2029286823 creator A5065833805 @default.
• W2029286823 creator A5066136399 @default.
• W2029286823 creator A5068550336 @default.
• W2029286823 creator A5074738342 @default.
• W2029286823 creator A5080693514 @default.
• W2029286823 creator A5081241155 @default.
• W2029286823 creator A5085987481 @default.
• W2029286823 date "2014-11-30" @default.
• W2029286823 modified "2023-09-25" @default.
• W2029286823 title "First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer" @default.
• W2029286823 cites W1498471683 @default.
• W2029286823 cites W1594020010 @default.
• W2029286823 cites W1977267072 @default.
• W2029286823 cites W1981711832 @default.
• W2029286823 cites W1984418041 @default.
• W2029286823 cites W1999065747 @default.
• W2029286823 cites W2000954296 @default.
• W2029286823 cites W2004691500 @default.
• W2029286823 cites W2006771504 @default.
• W2029286823 cites W2009886463 @default.
• W2029286823 cites W2014031706 @default.
• W2029286823 cites W2014096417 @default.
• W2029286823 cites W2017739035 @default.
• W2029286823 cites W2019607817 @default.
• W2029286823 cites W2020372547 @default.
• W2029286823 cites W2025188980 @default.
• W2029286823 cites W2027114592 @default.
• W2029286823 cites W2070732456 @default.
• W2029286823 cites W2073100248 @default.
• W2029286823 cites W2074696167 @default.
• W2029286823 cites W2077223675 @default.
• W2029286823 cites W2086924064 @default.
• W2029286823 cites W2100490225 @default.
• W2029286823 cites W2101982508 @default.
• W2029286823 cites W2107223717 @default.
• W2029286823 cites W2109439031 @default.
• W2029286823 cites W2114553148 @default.
• W2029286823 cites W2114735994 @default.
• W2029286823 cites W2116056409 @default.
• W2029286823 cites W2120943945 @default.
• W2029286823 cites W2124378682 @default.
• W2029286823 cites W2129172946 @default.
• W2029286823 cites W2139810669 @default.
• W2029286823 cites W2141134269 @default.
• W2029286823 cites W2143695256 @default.
• W2029286823 cites W2150575159 @default.
• W2029286823 cites W2154608911 @default.
• W2029286823 cites W2155263737 @default.
• W2029286823 cites W2161810908 @default.
• W2029286823 cites W2165404212 @default.
• W2029286823 cites W2220670435 @default.
• W2029286823 cites W2261189152 @default.
• W2029286823 cites W2273740586 @default.
• W2029286823 cites W2520051342 @default.
• W2029286823 cites W2524390625 @default.
• W2029286823 cites W2591434114 @default.
• W2029286823 cites W4235501371 @default.
• W2029286823 doi "https://doi.org/10.1158/1078-0432.ccr-14-1315" @default.
• W2029286823 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4254850" @default.
• W2029286823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25231405" @default.
• W2029286823 hasPublicationYear "2014" @default.
• W2029286823 type Work @default.
• W2029286823 sameAs 2029286823 @default.
• W2029286823 citedByCount "34" @default.
• W2029286823 countsByYear W20292868232015 @default.
• W2029286823 countsByYear W20292868232016 @default.
• W2029286823 countsByYear W20292868232017 @default.
• W2029286823 countsByYear W20292868232018 @default.
• W2029286823 countsByYear W20292868232019 @default.
• W2029286823 countsByYear W20292868232020 @default.
• W2029286823 countsByYear W20292868232021 @default.
• W2029286823 countsByYear W20292868232022 @default.
• W2029286823 countsByYear W20292868232023 @default.
• W2029286823 crossrefType "journal-article" @default.
• W2029286823 hasAuthorship W2029286823A5001343667 @default.
• W2029286823 hasAuthorship W2029286823A5002405477 @default.
• W2029286823 hasAuthorship W2029286823A5003564280 @default.
• W2029286823 hasAuthorship W2029286823A5009096434 @default.
• W2029286823 hasAuthorship W2029286823A5010813520 @default.
• W2029286823 hasAuthorship W2029286823A5016550047 @default.
• W2029286823 hasAuthorship W2029286823A5021317857 @default.
• W2029286823 hasAuthorship W2029286823A5032401979 @default.
• W2029286823 hasAuthorship W2029286823A5034748028 @default.
• W2029286823 hasAuthorship W2029286823A5041984199 @default.

• next